Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Trends Cell Biol. 2021 Apr;31(4):237-240. doi: 10.1016/j.tcb.2021.01.007. Epub 2021 Feb 13.
Recent innovations in immunotherapies have cured cancers but remain ineffective in pancreatic cancer, which exhibits intertwined dynamics of dedifferentiation of epithelium and reprogramming of immunosuppression. Emerging evidence reveals the biological mechanisms through which dedifferentiation recapitulates immune reprogramming, providing new insights into the therapeutic potential of controlling dedifferentiation for sensitization to immunotherapies.
最近的免疫疗法创新已经治愈了一些癌症，但在胰腺癌中仍然无效，胰腺癌表现出上皮去分化和免疫抑制重新编程的交织动态。新出现的证据揭示了去分化重新编程免疫的生物学机制，为控制去分化以增强对免疫疗法的敏感性的治疗潜力提供了新的见解。
